Vaxcyte Income Statement (2019-2026) | PCVX

Income Statement Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Operating items
Research & Development (Quarter)
17.65M20.43M23.07M31.68M38.47M47.68M51.63M58.08M72.69M97.42M104.15M94.59M131.51M116.94M133.61M148.13M194.18M209.93M242.06M312.78M
Selling, General & Administrative (Quarter)
6.08M6.52M6.77M7.54M9.42M10.90M11.95M13.11M14.46M15.61M17.53M19.89M21.47M22.99M28.55M32.66M32.04M32.45M32.22M33.07M
Other Operating Expenses (Quarter)
23.00M75.00M
Operating Expenses (Quarter)
23.73M26.95M29.85M39.22M47.89M58.58M86.57M71.19M87.15M113.03M196.68M114.47M152.98M139.92M162.17M180.79M226.22M242.38M274.28M345.85M
Operating Income (Quarter)
-23.73M-26.95M-29.85M-39.22M-47.89M-58.58M-86.57M-71.19M-87.15M-113.03M-196.68M-114.47M-152.98M-139.92M-162.17M-180.79M-226.22M-242.38M-274.28M-345.85M
EBIT (Quarter)
-23.73M-26.95M-29.85M-39.22M-47.89M-58.58M-86.57M-71.19M-87.15M-113.03M-196.68M-114.47M-152.98M-139.92M-162.17M-180.79M-226.22M-242.38M-274.28M-345.85M
Non-operating items
Interest & Investment Income (Quarter)
0.09M0.09M0.10M0.13M0.40M1.19M6.63M10.39M16.45M18.50M17.57M21.67M23.81M28.06M36.46M32.94M31.07M29.26M26.45M26.61M
Other Non Operating Income (Quarter)
-0.41M0.34M1.28M0.23M-0.65M0.66M11.25M-0.32M-0.11M0.23M-47.03M-2.21M0.47M8.74M-11.37M7.14M28.57M0.29M1.32M-1.38M
Non Operating Income (Quarter)
0.05M0.34M1.28M0.23M-0.65M0.66M8.52M10.73M18.81M20.36M15.88M19.45M24.28M36.80M25.09M40.08M59.65M29.55M27.78M25.23M
Net income details
EBT (Quarter)
-23.64M-26.86M-29.75M-39.09M-47.49M-57.39M-79.94M-60.80M-70.70M-94.53M-179.11M-92.81M-129.17M-111.87M-125.71M-147.86M-195.15M-213.12M-247.83M-319.24M
Profit After Tax (Quarter)
-23.68M-26.61M-28.56M-38.99M-48.53M-57.92M-78.05M-60.46M-68.34M-92.66M-180.80M-95.02M-128.70M-103.12M-137.08M-140.72M-166.57M-212.83M-246.51M-320.62M
Income from Continuing Operations (Quarter)
-23.64M-26.86M-29.75M-39.09M-47.49M-57.39M-79.94M-60.80M-70.70M-94.53M-179.11M-92.81M-129.17M-111.87M-125.71M-147.86M-195.15M-213.12M-247.83M-319.24M
Consolidated Net Income (Quarter)
-23.64M-26.86M-29.75M-39.09M-47.49M-57.39M-79.94M-60.80M-70.70M-94.53M-179.11M-92.81M-129.17M-111.87M-125.71M-147.86M-195.15M-213.12M-247.83M-319.24M
Income towards Parent Company (Quarter)
-23.64M-26.86M-29.75M-39.09M-47.49M-57.39M-79.94M-60.80M-70.70M-94.53M-179.11M-92.81M-129.17M-111.87M-125.71M-147.86M-195.15M-213.12M-247.83M-319.24M
Net Income towards Common Stockholders (Quarter)
-23.68M-26.61M-28.56M-38.99M-48.53M-57.92M-78.05M-60.46M-68.34M92.66M-623.73M-92.81M-129.17M-111.87M-125.71M-147.86M-195.15M-213.12M-247.83M-319.24M
Additional items
EPS (Basic) (Quarter)
-0.46-0.51-0.54-0.68-0.80-0.93-1.02-0.70-0.70-0.91-1.82-0.85-1.10-0.83-1.02-1.04-1.22-1.56-1.80-2.30
EPS (Weighted Average and Diluted) (Quarter)
-0.46-0.51-0.54-0.68-0.80-0.93-1.02-0.70-0.70-0.91-1.82-0.85-1.10-0.83-1.02-1.04-1.22-1.56-1.80-2.30
Shares Outstanding (Weighted Average) (Quarter)
51.34M52.19M51.92M57.55M60.82M60.17M64.88M86.21M98.06M101.67M97.16M111.69M117.26M117.60M122.00M135.69M135.86M135.98M136.09M139.51M
Shares Outstanding (Diluted Average) (Quarter)
51.34M51.63M51.92M57.55M59.19M61.99M64.88M86.21M92.17M101.67M97.16M111.69M117.26M123.69M122.00M135.69M136.03M135.98M136.09M139.51M
EBITDA (Quarter)
-23.73M-26.95M-29.85M-39.58M-47.89M-58.58M-86.57M-60.05M-70.91M-92.43M-178.33M-92.31M-129.78M-104.80M-141.09M-137.17M-168.14M-210.09M-245.78M-329.04M
Interest Expenses (Quarter)
0.01M0.00M
Shares Outstanding (Quarter)
51.96M52.59M53.03M56.50M58.62M60.57M79.47M80.64M93.81M95.10M95.36M108.76M110.58M124.43M124.89M128.94M129.82M130.03M131.06M144.31M